Metabolic dysfunction-associated steatotic liver disease (MASLD) has emerged as a formidable global health challenge, representing one of the leading causes of chronic liver disease worldwide. This condition encompasses a broad spectrum of hepatic pathologies, ranging from isolated fat accumulation in the liver (hepatic steatosis) to advanced fibrosis and cirrhosis. The escalating prevalence of MASLD parallels the global rise in obesity, insulin resistance, and metabolic syndrome, underscoring the critical need for innovative and effective therapeutic strategies. Historically, the armamentarium against MASLD, particularly its more severe inflammatory form, metabolic dysfunction-associated steatohepatitis (MASH), has been disappointingly limited, relying primarily on lifestyle modification without approved pharmacologic interventions.
Recent years, however, have ushered in a transformative era in the therapeutic landscape of MASH, catalyzed by the landmark conditional approvals of resmetirom and semaglutide by the FDA. These approvals signify a monumental shift, as they represent the first pharmacological agents validated to directly address key pathophysiological drivers of MASH. Resmetirom, a selective thyroid hormone receptor beta agonist, targets hepatic lipid metabolism, thereby promoting fat clearance from the liver. Semaglutide, a glucagon-like peptide-1 receptor agonist originally developed for diabetes, exerts pleiotropic benefits including weight reduction, improved insulin sensitivity, and likely anti-inflammatory effects within hepatic tissue. Together, these agents validate the strategy of confronting both the upstream metabolic dysfunction and the subsequent intrahepatic injury inherent in MASH pathogenesis.
Pivotal clinical trials supporting these agents have also highlighted the complexity and heterogeneity inherent to MASLD/MASH, driving renewed interest in rational combination treatments. The premise is that monotherapy may be insufficient given the multiplicity of pathogenic mechanisms—ranging from lipotoxicity and oxidative stress to inflammation and fibrogenesis. Tailoring treatment regimens according to individual patient phenotypes and disease stages could therefore optimize therapeutic efficacy and safety. This personalized approach is further bolstered by the increasing understanding of the metabolic milieu and hepatic cellular pathways involved, enabling the design of interventions that precisely target distinct molecular and pathological processes.
Nonetheless, significant challenges remain in evolving MASH care from a conceptual to a clinical reality. One major hurdle is the persistent reliance on liver biopsy as the gold-standard diagnostic and monitoring tool. Biopsy is invasive, costly, and prone to sampling variability, which complicates both clinical decision-making and the conduct of clinical trials. The absence of dynamic, validated biomarkers that can accurately reflect disease activity and response to therapy limits the ability to personalize treatment and monitor its effectiveness longitudinally. This shortfall is compounded by high placebo response rates in many trials, possibly reflecting the impact of lifestyle changes and the natural variability of disease, which confounds interpretation of investigational drug efficacy.
To circumvent these limitations, emerging noninvasive diagnostic approaches are gaining traction. Advanced imaging modalities, such as magnetic resonance elastography and proton density fat fraction quantification, offer safer, reproducible alternatives to biopsy for assessing hepatic steatosis and fibrosis. Concurrently, the integration of multi-omic profiling—including genomics, transcriptomics, proteomics, and metabolomics—provides unprecedented resolution into the molecular underpinnings of MASLD. Such comprehensive profiling facilitates the identification of novel biomarkers and therapeutic targets, enabling more precise patient stratification, enrichment in clinical trials, and real-time monitoring of disease progression or regression.
The synthesis of insights from prior clinical trials reveals critical lessons for future drug development in MASLD. Agents that exert pleiotropic metabolic effects while simultaneously addressing hepatic inflammation and fibrosis offer promise, but must be precisely matched to patient characteristics to maximize benefit. Additionally, the timing of therapeutic intervention is crucial; early-stage disease may respond best to metabolic modulation, whereas advanced fibrosis may necessitate agents with direct antifibrotic properties. The paradigm is clearly moving toward a mechanism-aligned, personalized therapeutic model rather than a one-size-fits-all solution.
A pragmatic framework for personalized MASH management therefore integrates lifestyle interventions with pharmacotherapies targeted at distinct but interconnected pathophysiological nodes. Lifestyle modification remains the foundational component, with diet, exercise, and weight management providing the basis upon which pharmacologic agents can build. Incretin-based therapies, exemplified by semaglutide, offer profound metabolic benefits, improving glycemic control, reducing adiposity, and potentially mitigating hepatic inflammation. Liver-directed agents, including resmetirom and emerging antifibrotics, are deployed to directly counteract hepatic steatosis, inflammation, and fibrogenesis. This combinatorial approach aims not only to arrest disease progression but also to prevent liver-related complications such as hepatocellular carcinoma and decompensated cirrhosis.
Moreover, management strategies must extend beyond liver disease per se, encompassing the broader cardiometabolic risk landscape that plagues patients with MASLD. Cardiovascular disease remains the leading cause of death in this population, and therapeutic regimens that concomitantly improve hepatic and systemic metabolic parameters hold the greatest promise. The advent of agents that modulate multiple pathways simultaneously, or rational combinations thereof, thus has the potential to reduce both hepatic morbidity and excess cardiovascular mortality, addressing MASLD as a multisystem disorder.
The future of MASLD therapeutics also hinges on leveraging advancements in digital technology and big data analytics. Artificial intelligence and machine learning algorithms applied to multi-omic datasets and clinical phenotyping can help decode the extensive heterogeneity of disease biology and patient response patterns. Such tools are poised to revolutionize patient selection, treatment optimization, and monitoring, transforming clinical trials from broad-based recruitment to highly selective, enriched designs that accelerate drug development timelines and reduce costs.
In conclusion, the landscape of metabolic dysfunction-associated steatohepatitis management is experiencing a revolutionary transformation backed by fundamental advances in our understanding of disease mechanisms, diagnostic capabilities, and pharmacotherapy. The conditional approvals of resmetirom and semaglutide herald new hope, fostering momentum for the rapid introduction of additional novel agents currently in late-stage development. Addressing ongoing challenges such as the need for robust biomarkers, reducing placebo effects, and dealing with disease heterogeneity will be essential for translating therapeutic innovation into improved patient outcomes. Ultimately, adopting a personalized, mechanism-based treatment approach integrating lifestyle, metabolic modulation, and liver-directed therapy is critical to mitigating MASLD’s burden and reducing its global impact.
The paradigm shift in MASH care offers a blueprint for managing complex metabolic diseases intersecting multiple organ systems. By embracing precision medicine principles and incorporating technological advances in diagnostics and data interpretation, clinicians can provide individualized therapy that not only halts liver disease progression but also ameliorates systemic metabolic dysfunction. As research and clinical practice continue to evolve, the promise of personalized care for MASLD may soon become a clinical reality, transforming lives and reducing the toll of this pervasive, multisystem disorder.
Subject of Research: Therapeutic strategies and personalized management of metabolic dysfunction-associated steatohepatitis (MASH) within the broader spectrum of metabolic dysfunction-associated steatotic liver disease (MASLD).
Article Title: Therapeutic targets for metabolic dysfunction-associated steatohepatitis: a personalized approach to disease management.
Article References:
Rinella, M.E., Sookoian, S. Therapeutic targets for metabolic dysfunction-associated steatohepatitis: a personalized approach to disease management. Nat Rev Gastroenterol Hepatol (2026). https://doi.org/10.1038/s41575-026-01187-8
Image Credits: AI Generated
DOI: https://doi.org/10.1038/s41575-026-01187-8
Keywords: MASLD, MASH, metabolic dysfunction-associated steatotic liver disease, metabolic dysfunction-associated steatohepatitis, resmetirom, semaglutide, liver fibrosis, noninvasive biomarkers, multi-omic profiling, personalized medicine, liver-directed therapy, cardiovascular risk, combination therapy
